Everything below concerns Ac-LKKTETQ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Banking, monetary and fiscal policy is overseen by the European Central Bank, member states, and the EU Commission. This is vital for European society as it affects the human rights to full employment, to fair wages, housing, and to an adequate standard of living. When the Eurozone and common currency of the euro was established, there was no political agreement to develop a full EU fiscal policy (i.e. tax and spending), so that governments would pool money and lend to countries in trouble, because it was thought that wealthier member states should not have to subsidise poorer member states. However, there was planned to be a common central bank, which would aim to have common interest rates. The ECB, based in Frankfurt, controls monetary policy that underpins the euro. Member states also have central banks (such as the Bundesbank, Banque de France, Banco de España), and these 19 Eurozone member state central banks have a duty to act compatibly with ECB policy. The ECB has an executive board with a president, vice president and four other members, all appointed by the European Council by qualified majority, after consulting the European Parliament, and the Governing Council of the ECB. The Governing Council is made up of the ECB executive board and member state central banks using the euro, they have 8 year terms, and can be removed only for gross misconduct.
== Family == Eastlack lived in Philadelphia, Pennsylvania, with his sister and his parents. Eastlack was of Anglo-Scottish, Irish, and German descent, and his father was a World War I military veteran and a firefighter. Harry's elder sister Helene Davridge (née Eastlack) was born on (1932-08-20)20 August 1932 in Philadelphia, Pennsylvania, and became a music teacher later as an adult. She died in September 1998, at the age of 66, in Sharon Hill, Pennsylvania, leaving behind her husband and daughter, Kristen.
=== Redox === Polycyclic aromatic compounds characteristically yield radicals and anions upon treatment with alkali metals. The large PAH form dianions as well. The redox potential correlates with the size of the PAH.
On 21 July, the Syrian Observatory for Human Rights said that nine civilians were injured by a drone attack on the city of Shahba by Bedouin tribes. On 25 July, the Syrian Observatory for Human Rights reported ceasefire violations in Umm al-Zaytoun village and areas of Reema Hazem and in Walgha. Tensions persisted in the Kanaker region with the presence of tribal gunmen. On 26 July, the spiritual leadership of the Druze, headed by Sheikh Hikmat al-Hijri, announced the formation of a "Supreme Legal Committee" consisting of six judges, including four judicial advisors, and three lawyers. The committee outlined its responsibilities as managing public affairs across all sectors in Suwayda, including administrative, security, and service-related matters.
=== 1950s onward === The advent in the 1950s of fibrous synthetics such as nylon, polyethylene, polypropylene, and polyvinyls provided new materials from which researchers and doctors in the field of wound care could explore better protecting of healing wounds and even accelerating the natural wound healing process. In the 1960s, research and articles by George Winter and Howard Maibach reported on the superior efficacy of moist wound dressings. The adoption of moist wound dressing technique as recommended best wound dressing practice reflected a large advance in approach producing markedly superior clinical outcomes. This dawn of modern wound care treatment initiated a process of improvement in the clinician's ability to bolster wound-site re-epithelialization and healing. The focus on evidence-based best practices and research continues. In the 1990s, improvements in composite and hybrid polymers expanded the range of materials available for wound dressing. Grafting and biotechnology have produced usable and useful protective covering of actual human skin generated through cloning procedures. These improvements, coupled with the developments in tissue engineering, have given rise to a number of new classes of wound dressings. One of these, "living skin equivalents," is often cited as a misnomer because they lack key components of whole living skin. "Living skin equivalents" may have the potential to serve as cellular platforms for the release of growth factors essential for proper wound healing.
Sources: en.wikipedia.org
=== Function during breastfeeding === Oxytocin has a crucial role in the process of milk ejection. After sucking, the release of oxytocin stimulates the myoepithelial cell contraction in the breast, which forces milk to move from the alveoli, via the milk ducts, and towards the nipple. Oxytocin is secreted quicker than prolactin. It facilitates the flow of pre-existing breast milk for the current feeding, hence helping the infant in obtaining milk easily.
Typical Neanderthal skull traits appear in the European fossil record near the beginning of the Middle Pleistocene, in specimens usually classified as H. heidelbergensis. These "pre-Neanderthals" seem to have gradually accreted these traits ("Neanderthalization") as populations adapted to the cold environment, evolving a "hyper-arctic" physique. Circumpolar peoples (namely Inuit groups) are often used as modern Neanderthal analogues to study "hyper-arctic" adaptations. Additionally, glacial periods may have forced populations into small refugia, reducing genetic diversity, leading to the development of other typical Neanderthal traits through genetic drift or pleiotropy. The 120,000 to 140,000-year-old Israeli Nesher Ramla remains may represent one such source population which would recolonise Europe following the Penultimate Glacial Period. The occurrence of typical Neanderthal traits in the Middle Pleistocene was highly variable even among individuals of the same population. The speed of Neanderthalization may have also been impeded by gene flow between Western Europe and Africa; this is exemplified by anomalous specimens which lack typical Neanderthal traits, such as Ceprano Man. The first recognisable "early Neanderthals" show up in the fossil record by the end of Marine Isotope Stage 7 (beginning roughly 243,000 years ago) and give way to "classic" or "late Neanderthals" by the end of Marine Isotope Stage 5e. This spans the Penultimate Glacial Period to the Last Interglacial.
== Taxonomy == Carl Linnaeus described the species in 1771, the specific epithet biloba derived from the Latin bis, "twice" and loba, "lobed", referring to the shape of the leaves. Two names for the species recognise the botanist Richard Salisbury, a placement by Nelson as Pterophyllus salisburiensis and the earlier Salisburia adiantifolia proposed by James Edward Smith. The epithet of the latter may have been intended to denote a characteristic resembling Adiantum, the genus of maidenhair ferns. The generic name Ginkgo can be traced to recordings done by Engelbert Kaempfer, the first Westerner to investigate the species in 1690 in Nagasaki, for the Amoenitates Exoticae (1712): it is regarded as a mistranscription of Japanese 銀杏 ginkyō ([ɡiŋkʲoː]). Taking his spelling of other Japanese words containing the syllable [kʲoː] (present romanization: kyō) into account, an expected transcription would have been "ginkio" or "ginkjo". Thus, his curious "–kgo" spelling has long been considered to be an error Kaempfer made in his notes, but Nagata et al. showed that it was the spelling of his interpreter, Genemon Imamura, who spoke the local Nagasaki dialect. Linnaeus adopted the ginkgo spelling based on Kaempfer's compilation of Japanese flora in Amoenitates while writing Mantissa plantarum II (Amoenitates Exoticae, p. 811) thus becoming the tree's generic name. Kaempfer's drawing can be found in Hori's article.
==== Liquid ==== Metafluids offer programmable properties such as viscosity, compressibility, and optical. One approach employed 50-500 micron diameter air-filled elastomer spheres suspended in silicon oil. The spheres compress under pressure, and regain their shape when the pressure is relieved. Their properties differ across those two states. Unpressurized, they scatter light, making them opaque. Under pressure, they collapse into half-moon shapes, focusing light, and becoming transparent. The pressure response could allow them to act as a sensor or as a dynamic hydraulic fluid. Like cornstarch, it can act as either a Newtonian or a non-Newtonian fluid. Under pressure, it becomes non-Newtonian – meaning its viscosity changes in response to shear force.
=== 22 February === The SAF and the Sudan Shield Forces claimed to have forced the RSF to retreat from the Soba neighbourhood of eastern Khartoum and retook the Al-Lulua and Al-Samra neighbourhoods southeast of the Soba Bridge connecting Khartoum's southern and eastern neighbourhoods with the rural areas of East Nile, adding that the 17 RSF militants were killed while nine vehicles were destroyed or captured.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.